Skip to main content
Figure 1 | Journal of Experimental & Clinical Cancer Research

Figure 1

From: Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

Figure 1

Relationship between duration of PEGV therapy and final daily dose according to treatment regimen. Correlation between duration of PEGV therapy (months) and final daily PEGV dose (mg/day) in the total study population (A, upper panel, ●), Group 1 (B, middle panel, ■), and Group 2 (C, lower panel▲). Regression coefficients (r) and p values are shown.

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us